Latest news and press releases about NRx Pharmaceuticals, Inc. (NRXP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19.
Price
| Price | $3.35 |
| Market Cap | $58M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -741.91 |
| EV / EBITDA | -1.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 168.68% |
| Return on Invested Capital | -1855.48% |
| Return on Assets | -68.74% |
| Gross Margin | 32.68% |
| Operating Margin | -588.24% |
| Net Margin | -691.81% |
Related companies: COEP · CUE · EQ · HOWL · IOBT · IPSC · KPTI
Explore sector: Healthcare · Biotechnology
More sections of NRXP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks